Delta-Radiomics Based on Dynamic Contrast-Enhanced MRI Predicts Pathologic Complete Response in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy

Liangcun Guo 1,†, Siyao Du 1,†, Si Gao 1,*, Ruimeng Zhao 1, Guoliang Huang 1, Feng Jin 2, Yuee Teng 3,* and Lina Zhang 1,*

1 Department of Radiology, The First Affiliated Hospital of China Medical University, Shenyang 110001, China; guolc@cmu.edu.cn (L.G.); sydu@edu.cmu.cn (S.D.); gaosi@cmu.edu.cn (S.G.); rmzhao@cmu.edu.cn (R.Z.); gglhuang@cmu.edu.cn (G.H.)
2 Department of Breast Surgery, The First Affiliated Hospital of China Medical University, Shenyang 110001, China; jinfeng@cmu.edu.cn
3 Departments of Medical Oncology and Thoracic Surgery, The First Affiliated Hospital of China Medical University, Shenyang 110001, China
* Correspondence: yeteng@cmu.edu.cn (Y.T.); lnzhang@cmu.edu.cn (L.Z.); Tel.: +86-021-83282447 (L.Z.)
† These authors contributed equally to this work.

Simple Summary: Neoadjuvant chemotherapy (NAC) followed with surgery is the standard strategy in the treatment of locally advanced breast cancer, but the individual efficacy varies. Early and accurate prediction of complete responders determines the NAC regimens and prognosis. Breast MRI has been recommended to monitor NAC response before, during, and after treatment. Radiomics has been heralded as a breakthrough in medicine and regarded to have changed the landscape of biomedical research in oncology. Delta-radiomics characterizing the change in feature values by applying radiomics to multiple time points, is a promising strategy for predicting response after NAC. In our study, the delta-radiomics model built with the change of radiomic features before and after one cycle NAC could effectively predict pathological complete response (pCR) in breast cancer. The model provides strong support for clinical decision-making at the earliest stage and helps patients benefit the most from NAC.

Abstract: Objective: To investigate the value of delta-radiomics after the first cycle of neoadjuvant chemotherapy (NAC) using dynamic contrast-enhanced (DCE) MRI for early prediction of pathological complete response (pCR) in patients with breast cancer. Methods: From September 2018 to May 2021, a total of 140 consecutive patients (training, n = 98; validation, n = 42), newly diagnosed with breast cancer who received NAC before surgery, were prospectively enrolled. All patients underwent DCE-MRI at pre-NAC (pre-) and after the first cycle (1st-) of NAC. Radiomic features were extracted from the postcontrast early, peak, and delay phases. Delta-radiomics features were computed in each contrast phases. Least absolute shrinkage and selection operator (LASSO) and a logistic regression model were used to select features and build models. The model performance was assessed by receiver operating characteristic (ROC) analysis and compared by DeLong test. Results: The delta-radiomics model based on the early contrast phases of DCE-MRI combined clinicopathology information could predict pCR after one cycle of NAC in patients with breast cancer.
Keywords: DCE-MRI; breast cancer; radiomics; neoadjuvant chemotherapy; pathological complete response

1. Introduction

As a standard care for locally advanced breast cancer, neoadjuvant chemotherapy (NAC) is clinically useful to downsize and downstage tumors and reduce the extent of surgery from mastectomy to breast conservation. Less than 10% to 50% of patients achieve pathological complete response (pCR) through NAC depending on receptor status and subtype [1]. Achieving pCR can result in a more favorable long-term prognosis [2–4]. If we can confidently predict that a patient has a high probability of pCR, surgery can be safely postponed or even omitted. Thus, predicting the likelihood of pCR is important for the development of improved and personalized treatment plans. The earlier accurate predictions are made, the more likely patients are to benefit. Therefore, early and reliable predictors of tumor response are needed.

Breast MRI is recommended to monitor therapy response during NAC [5,6], with dynamic contrast-enhanced MRI (DCE-MRI) providing vascular information to evaluate tumor presence with high sensitivity. Tumor morphology, vascularity, and cell density can be affected by NAC. Many feature-level MRI metrics have been explored to monitor treatment response, including tumor size [7–10], DCE kinetic parameters [7,11,12], diffusion measures [8,13], and MRI texture parameters [14–16]. Recent studies [17–20] have demonstrated the feasibility of radiomics for predicting NAC response. Most radiomics studies about breast cancer [18–20] extracted radiomic features from single time-point images (e.g., before NAC). However, these studies generally neglect the changes in tumors during NAC. Delta-radiomics is a new concept based on the changes in radiomic features in a set of longitudinal images [21]. Therapy-induced changes in tumor morphology and heterogeneity can be quantified using delta-radiomics as a complement to response evaluation criteria in solid tumor (RECIST) for monitoring therapeutic response in several tumor types [22,23]. In the field of breast cancer, key radiomic features associated with the pathological response were significantly different before and after NAC [24]. Fan et al. [25] evaluated the delta-radiomic model after the second cycle of NAC using DCE-MRI. However, whether the delta-radiomics model can predict NAC response after the first cycle, which is the earliest time-point, remains unclear.

We assumed that delta-radiomics could reflect changes in tumor heterogeneity or genetic profiles after only one cycle of NAC. The main objective of this work was to determine whether therapy-induced delta-radiomics features can improve models for predicting NAC outcomes when used in conjunction with longitudinal fusion radiomic features. Additionally, we also used differential subsampling with cartesian ordering (DISCO) DCE-MRI, which has high spatiotemporal resolution [26], to analyze the model performance in the early, peak, and delay phases during contrast agent inflow and outflow, and determine the optimal contrast phase of DCE-MRI.

2. Materials and Methods

2.1. Patients

The prospective protocol was approved by our Institutional Review Board (approval code: 2019-33-2), and each participant provided written informed consent.

In the prospective study, the inclusion criteria were as follows: (1) the patient had biopsy-proven unilateral primary breast invasive ductal cancer and ipsilateral axillary lymph node metastasis without prior treatment; (2) complete biopsy information including histological grades, receptor status, and Ki-67 level of the primary tumor was available; and (3) baseline DCE-MRI and DCE-MRI following the first cycle of NAC were conducted. The exclusion criteria were as follows: (1) occult cancers or small lesions less than 1.0 cm in diameter on baseline DCE-MRI; (2) large lesions more than 10.0 cm in diameter; (3) incomplete NAC cycle or change in chemotherapy regimen during NAC; (4) surgery after NAC...
was performed in an external institution. Figure 1 shows a flowchart of patient collection. From March 2019 to May 2021, the consecutive cohort enrolled in our study included a total of 162 patients with paired DCE-MRI (baseline DCE-MRI and DCE-MRI following the first cycle of NAC). According to the exclusion criteria, 22 patients were excluded due to occult primary foci ($n = 2$), small lesions ($n = 6$), oversized lesions ($n = 3$), incomplete NAC cycle ($n = 3$), change in chemotherapy regimen ($n = 6$), and undergoing surgery at an external institution ($n = 2$). Based on their admission time, the remaining 140 patients were split into a training cohort and a validation cohort at a ratio of 7:3 (98 patients for training and 42 patients for validation).

![Flowchart of patient collection](image)

**Figure 1.** Flowchart of patient collection. NAC, neoadjuvant chemotherapy; DCE-MRI, dynamic contrast-enhanced.

### 2.2. DCE-MRI Data Acquisition

Pretreatment MRI was performed within one week before NAC. Follow-up MRI after the first cycle of NAC was performed within 72 h before the second cycle of NAC. Both breast MRI examinations were performed using a 3 T MR scanner (SIGNATM Pioneer, GE Healthcare, Milwaukee, WI, USA) with an 8-channel phased-array breast coil. T1-weighted DCE-MRI sequence (one pre-contrast phase and 20 post-contrast phases with temporal resolution of 19.4 s) was obtained using three-dimensional (3D) DISCO and fat suppression technique (GE Healthcare). The scanning parameters were as follows: TR = 4.9 ms, TE = 1.7 ms, flip angle = 90°, FOV = 360 × 360 mm, matrix = 256 × 256, section thickness = 1.4 mm, intersection gap = 1.4 mm, number of sections = 120/phase, acceleration factors = 2. After the first pre-contrast scanning followed by a pause of 20 s, the contrast agent was injected intravenously as a bolus (0.1 mmol/kg body weight) by a power injector at 2 mL/s followed by a 20 mL saline flush. Subsequently, 20 phase post-contrast images were acquired.

### 2.3. Clinicopathologic Features

Estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) were evaluated according to ASCO/USCAP guidelines [27,28] using an avidin–biotin immunohistochemistry technique for biopsy specimens before NAC.
The Ki-67 index was assessed with a cut-off value of 20% [29]. The molecular subtype was categorized according to the 2017 St. Gallen guidelines [30]. Patients with hormone receptor (HR)-positive, low Ki-67, and HER2-negative in breast tumors were defined as luminal A subtype. Luminal B subtype included patients with HR-positive, high Ki-67, or HER2-positive. If HR-negative, HER2-enriched subtype patients were distinguished by HER2 overexpression or overamplification, whereas those with HER2-negative breast tumors were classified as triple-negative subtype patients. For multi-lesion patients, the receptor state of the largest lesion was selected for assessment.

2.4. NAC Regimen and Criteria for pCR

According to the National Comprehensive Cancer Network guideline [31], all participants received the standard six or eight cycles of NAC before surgery. The NAC regimens were based on taxane, anthracycline, or both anthracycline and taxane. For HER2-positive tumors, anti-HER2-targeted trastuzumab or trastuzumab + pertuzumab were added to the chemotherapy drugs (8 mg/kg as the loading dose and 6 mg/kg as the maintenance dose).

Treatment response was evaluated after all NAC cycles based on surgical specimens. pCR was defined as the absence of residual invasive tumor (Miller–Payne grade 5, residual ductal carcinoma in situ could be present) and the absence of lymph node invasion in the ipsilateral sentinel node or lymph nodes removed during axillary dissection (ypT0/isN0) [3,8,13,14,18,32].

2.5. Tumor Segmentation and Repeatability Analysis

The radiomics workflow is illustrated in Figure 2. For the pre-treatment and post-treatment DCE-MRI for all patients, the open-source ITK-snap software (www.itksnap.org, version 3.8.0) (accessed on 28 July 2020) was imported to segment the volume of interest (VOI) [33]. Each tumor lesion was semi-automatically segmented on the peak contrast phase (8th post-contrast phase according to time intensity curve [TIC]) of DCE-MRI (CEp). By using region growing methods, the tumor VOIs covered the tumor areas. If deemed necessary, manual adjustments were made dominantly in the axial position, auxiliary by the coronal and sagittal positions. Necrosis and blood areas were included in the tumor VOIs. If the tumor was a unilateral multifocal and multicentric lesion, the largest one was selected as the object. The tumor VOIs on the CEp images were propagated with slight adjustment to the early contrast phase of DCE-MRI (CEe; 5th post-contrast phase according to TIC) and the delay contrast phase of DCE-MRI (CED; 18th post-contrast phase according to TIC) (Supplementary Figure S1).

Two radiologists with two and five years of experience in breast cancer diagnosis independently performed VOI delineation to test intra-observer reproducibility. They independently segmented the pretreatment MRI CEp images of breast cancer in 30 randomly selected samples. The radiomic features extracted from the above two VOIs were compared using the intra-class correlation coefficient (ICC). An ICC value of 0.8 or greater was considered to indicate almost perfect consistency, and the feature was retained. Features with ICC values less than 0.8 were initially eliminated. Then, the VOIs delineated by the radiologist with two years of experience were used as the final segmentation.
Figure 2. Workflow of the radiomics analysis. Pre, pre-NAC; 1st, the first cycle of NAC; CEe, the early phase of DCE-MRI; CEp, the peak phase of DCE-MRI; CEd, the delay phase of DCE-MRI; Delta, delta-radiomics features (the relative change values between pre- and 1st-radiomics features); LASSO, the least absolute shrinkage and selection operator; CV, cross-validation; ROC curve, the receiver operating characteristic curve.

2.6. Radiomic Features and Their Changes

The radiomic features of the DCE-MRI images before NAC and after the first cycle were extracted using Analysis Kit software (A.K., GE Healthcare). For each VOI, the extracted features included seven categories of original image features: (1) first-order features ($n = 18$);
(2) 2D and 3D shape features \((n = 14)\); (3) gray-level co-occurrence matrix features (GLCM; \(n = 24\)); (4) gray-level run length matrix features (GLRLM, \(n = 16\)); (5) gray-level size zone matrix features (GLZSM, \(n = 16\)); (6) neighboring gray-tone difference matrix features (NGTDM, \(n = 5\)); (7) gray-level dependence matrix features (GLDM, \(n = 14\)); and (8) their wavelet-transformed type \((n = 744)\). There is a total of 851 radiomic features, which have been used in previous studies \([18, 24, 25, 32, 34]\). Detailed names and definitions of all features can be found in Supplementary Data S1.

The changes in the radiomic features (delta-radiomics features) between CEe, CEp, and CEd were calculated from the differences between the pre-NAC features values (pre-radiomics features) and the 1st-NAC features values (1st-radiomics features):

\[
\text{Delta-radiomics features} = (\text{pre-radiomics features}) - (\text{1st-radiomics features}) \tag{1}
\]

### 2.7. Feature Selection

All patients in the training cohort were used to select features and build the prediction model. Separate pre-, 1st-, and delta-radiomics features under different contrast phases were selected. Before dimensionality reduction, features with variance \(\leq 1\) were excluded from analyses. The data were standardized (Z-score) using the following equation:

\[
\text{Standardized value} = (\text{original value} - \text{average value})/\text{standard deviation} \tag{2}
\]

To obtain the features that were most strongly associated with pCR in the training cohort, we first performed Student’s t-test and univariate logistic regression analysis, and features with \(p < 0.1\) were used for subsequent analysis. Spearman correlation analysis was then used to remove the features highly correlated with other features (the Spearman \(|p| \geq 0.9\)). Finally, the least absolute shrinkage and selection operator (LASSO), was used for fine feature selection. A 5-fold cross-validation was used to tune the parameters to find the best \(\lambda\) value. Since LASSO is a regularization method, it can reduce the regression coefficients of features that are considered as attribute noise to zero and identify features that are non-redundant and robust. Thus, LASSO can overcome overfitting and improve the generalization capability of the proposed machine learning model \([35]\).

### 2.8. Establishment and Performance of Models

#### 2.8.1. Separate Radiomic Models

In the training cohort, nine separate models under pre-, 1st-, delta-radiomics and different contrast phases were trained using multivariate logistic regression and 5-fold cross-validation, including model 1: pre-radiomics based on CEe; model 2: pre-radiomics based on CEp; model 3: pre-radiomics based on CEd; model 4: 1st-radiomics based on CEe; model 5: 1st-radiomics based on CEp; model 6: 1st-radiomics based on CEd; model 7: delta-radiomics based on CEe; model 8: delta-radiomics based on CEp; model 9: delta-radiomics based on CEd. The 5-fold cross-validation was used to optimize the tuning parameters to construct the multivariate logistic regression model. The validation cohort was used to evaluate the model performance. The radiomic score (Rad-score) for each patient in the training and validation cohort was computed. To assess the prediction performance, the receiver operating characteristic (ROC) curves were constructed, and the area under the ROC curves (AUCs) were calculated using the Rad-score. The performances of the separate pre-, 1st-, and delta-radiomics models under different contrast phases were compared using DeLong tests. The model with the largest AUC values and the AUC value more than 0.80 in the validation cohort was identified as the optimal model. The contrast phase of the optimal model was considered the optimal contrast phase for pCR classification.

#### 2.8.2. Longitudinal Fusion Radiomic Models

Longitudinal fusion radiomic models were established by combining longitudinal radiomic features based on the optimal contrast phases with the purpose of enhancing the predictive performance. After feature fusion, the methods of feature selection, model establishment, and model validation were the same as those for the separate models.
2.8.3. Clinical-Radiomics Models

The clinical-radiomic model was established based on the Rad-scores of the separate and longitudinal fusion radiomic models under optimal contrast phase along with significant clinical indicators to explore any improvement resulting from feature fusion. The models were trained, and validated using the same strategy used to develop the separate radiomic models as described above. The AUC, sensitivity, specificity, and accuracy of clinical-radiomics models will be calculated and presented.

2.9. Statistical Analysis

Clinicopathological characteristics and pretreatment MRI findings were compared between pCR and non-pCR using independent t-test or Mann–Whitney U test for continuous variables and chi-square test or Fisher’s exact test for categorical variables. The ROC curve was constructed to determine model performance based on the AUC, accuracy, sensitivity, and specificity. Calibration curves were used for each model to depict the agreement between the predicted probability of pCR and the observed outcomes. The Hosmer–Lemeshow test was used to determine the goodness of fit of the models, and p values of more than 0.05 were considered well calibrated. Decision curve analysis (DCA) was used to evaluate clinical utility by quantifying the net benefits of the training and validation cohort. The DeLong test was applied to compare the differences in the AUC values of different models. Heatmaps were generated to show the distribution between pCR and non-pCR. All statistical analyses were performed with R 4.1.1 and Python 3.70 (https://www.python.org/) (accessed on 28 July 2020). The R packages used in this study include “caret,” “glmnet,” “pROC,” “InformationValue,” “leaps,” and “bestglm.” A two-tailed p-value < 0.05 indicated statistical significance.

3. Results

3.1. Clinical Characteristics

A total of 140 lesions from 140 women (mean age, 50.51 years; age range, 28–73 years) were ultimately evaluated. Out of the 98 patients in the training cohort, 28 (28.6%) achieved pCR, while 12/42 patients (28.6%) in the validation cohort achieved pCR. For the classification of pCR, estrogen receptors, HER2 status, and molecular subtypes in both training and validation cohort, and progesterone receptors in training cohort were significantly different. The differences in the other clinical features and MRI morphology parameters were not statistically significant (Table 1).

Table 1. Comparison of clinicopathological characteristics in the training and validation cohort.

| Characteristics   | Training Cohort (n = 98) | Validation Cohort (n = 42) |
|-------------------|-------------------------|---------------------------|
|                   | pCR (n = 28) | Non-pCR (n = 70) | p | pCR (n = 12) | Non-pCR (n = 30) | p |
| Age (years)       | 51.0 ± 9.1 | 51.7 ± 10.5 | 0.601 | 50.7 ± 7.2 | 47.3 ± 10.7 | 0.242 |
| Tumor size (cm)   | 4.2 (3.1, 5.6) | 4.8 (3.4, 6.1) | 0.276 | 3.4 (2.5, 5.2) | 5.0 (3.1, 5.7) | 0.177 |
| Enhancement type (%) | 0.442 | | | | | |
| Mass-like         | 15 (53.6) | 42 (60) | | 7 (58.3) | 14 (46.7) | |
| Non-mass-like     | 6 (21.4) | 8 (11.4) | | 2 (16.7) | 4 (13.3) | |
| Mass + non-mass   | 7 (25.0) | 20 (28.6) | | 3 (25.0) | 12 (40.0) | |
| Type (%)          | | | | | | 0.236 |
| Multi-lesion      | 8 (28.6) | 29 (41.4) | | 3 (25.0) | 11 (36.7) | |
### Table 1. Cont.

| Characteristics          | Training Cohort (n = 98) | Validation Cohort (n = 42) |
|--------------------------|--------------------------|----------------------------|
|                          | pCR (n = 28)             | Non-pCR (n = 70)           | pCR (n = 12) | Non-pCR (n = 30) |
| Single-lesion            | 20 (71.4)                | 41 (58.6)                 | 9 (75.0)    | 19 (63.3)        |
| TNM (%)                  | 0.276                    |                            | 0.368       |                |
| II A                     | 7 (25.0)                 | 9 (12.9)                  | 3 (25.0)    | 7 (23.3)        |
| II B                     | 5 (17.9)                 | 18 (25.7)                 | 5 (41.7)    | 5 (16.7)        |
| III A                    | 2 (7.1)                  | 11 (15.7)                 | 2 (16.7)    | 5 (16.7)        |
| III B                    | 9 (32.1)                 | 26 (37.1)                 | 2 (16.7)    | 10 (33.3)       |
| III C                    | 5 (17.9)                 | 6 (8.6)                   | 0 (0.0)     | 3 (10.0)        |
| Grades (%)               | 0.104                    |                            | 0.205       |                |
| 2                        | 13 (46.4)                | 45 (64.3)                 | 10 (83.3)   | 19 (63.3)       |
| 3                        | 15 (53.6)                | 25 (35.7)                 | 2 (16.7)    | 11 (36.7)       |
| ER status (%)            | 0.001 *                  |                            | 0.002 *     |                |
| Positive                 | 5 (17.9)                 | 46 (65.7)                 | 2 (16.7)    | 21 (70.0)       |
| Negative                 | 23 (82.1)                | 24 (34.3)                 | 10 (83.3)   | 9 (30.0)        |
| PR status (%)            | 0.001 *                  |                            | 0.554       |                |
| Positive                 | 7 (25.0)                 | 49 (70.0)                 | 7 (58.3)    | 17 (56.7)       |
| Negative                 | 21 (75.0)                | 21 (30.0)                 | 5 (41.7)    | 13 (43.3)       |
| HER2 status (%)          | 0.041 *                  |                            | 0.008 *     |                |
| Positive                 | 15 (53.6)                | 22 (31.4)                 | 8 (66.7)    | 7 (23.3)        |
| Negative                 | 13 (46.4)                | 48 (68.6)                 | 4 (33.3)    | 23 (76.7)       |
| Ki-67 status (%)         | 0.092                    | <0.001 *                  | 0.263       |                |
| ≤20%                     | 2 (7.1)                  | 15 (21.4)                 | 1 (8.3)     | 23 (76.7)       |
| >20%                     | 26 (92.9)                | 55 (78.6)                 | 11 (91.7)   | 7 (23.3)        |
| Molecular subtypes (%)   | <0.001 *                 |                            | 0.046 *     |                |
| Luminal A                | 0 (0.0)                  | 5 (7.1)                   | 0 (0.0)     | 2 (6.7)         |
| Luminal B                | 7 (25.0)                 | 48 (68.6)                 | 5 (41.7)    | 19 (63.3)       |
| HER2 enriched            | 11 (39.3)                | 5 (7.1)                   | 5 (41.7)    | 2 (6.7)         |
| TN                       | 10 (35.7)                | 12 (17.2)                 | 2 (16.7)    | 7 (23.3)        |

Age is presented as mean ± SD. Tumor size is presented as median (interquartile range), and the others are shown as proportions (percentages). *p < 0.05. pCR, pathologic complete response; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; TN, triple negative.

#### 3.2. Repeatability Analysis

The ICCs for all radiomic features and their changes were greater than 0.80 between the two radiologists.

#### 3.3. Separate Radiomic Models

Table 2 shows the performances of the separate radiomic models under different contrast phases.
Table 2. Diagnostic performance of separate models.

|                  | CEE | CEp | CEd |
|------------------|-----|-----|-----|
| Pre-radiomics model |     |     |     |
| No. of selected features |     |     |     |
| LASSO_CV          | 9   | 9   | 2   |
| Logistic_CV       | 3   | 5   | 1   |
| AUC (training/validation) | 0.759/0.617 | 0.827/0.694 | 0.649/0.539 |
| 95% CI of AUC     | 0.647, 0.871/0.403, 0.830 | 0.723, 0.922/0.533, 0.856 | 0.527, 0.770/0.319, 0.759 |
| Sensitivity (training/validation) | 0.643/0.667 | 0.679/0.917 | 0.857/0.250 |
| Specificity (training/validation) | 0.800/0.633 | 0.857/0.500 | 0.386/0.967 |
| Accuracy (training/validation) | 0.755/0.643 | 0.806/0.619 | 0.520/0.762 |
| 1st-radiomics model |     |     |     |
| No. of selected features |     |     |     |
| LASSO_CV          | 10  | 9   | 13  |
| Logistic_CV       | 5   | 4   | 4   |
| AUC (training/validation) | 0.803/0.775 | 0.816/0.650 | 0.826/0.703 |
| 95% CI of AUC     | 0.694, 0.913/0.627, 0.923 | 0.717, 0.915/0.432, 0.868 | 0.738, 0.914/0.514, 0.892 |
| Sensitivity (training/validation) | 0.756/0.667 | 0.786/0.667 | 0.821/0.417 |
| Specificity (training/validation) | 0.771/0.800 | 0.771/0.800 | 0.700/0.967 |
| Accuracy (training/validation) | 0.776/0.762 | 0.776/0.667 | 0.735/0.810 |
| Delta-radiomics model |     |     |     |
| No. of selected features |     |     |     |
| LASSO_CV          | 13  | 11  | 3   |
| Logistic_CV       | 9   | 7   | 1   |
| AUC (training/validation) | 0.917/0.842 | 0.803/0.764 | 0.708/0.697 |
| 95% CI of AUC     | 0.861, 0.974/0.709, 0.974 | 0.64, 0.913/0.592, 0.936 | 0.594, 0.821/0.512, 0.883 |
| Sensitivity (training/validation) | 0.929/0.667 | 0.786/0.917 | 0.750/0.833 |
| Specificity (training/validation) | 0.829/0.900 | 0.771/0.667 | 0.629/0.700 |
| Accuracy (training/validation) | 0.857/0.833 | 0.776/0.738 | 0.663/0.738 |

The detailed features selected are described in Supplementary Data S2. For all models, the optimal performance appeared in the delta-radiomics model, which gave AUC values of 0.917 (95% CI: 0.861, 0.974) for the training cohort and 0.842 (95% CI: 0.709, 0.974) for the validation cohort using nine selected features under CEE. The delta-radiomics model performed better than the pre-radiomics model, which achieved AUC values of 0.759 (95% CI: 0.647, 0.871) for the training cohort and 0.617 (95% CI: 0.403, 0.830) for the validation cohort (DeLong test: \( p = 0.011/0.047 \) for training/validation cohort). The performance of 1st-radiomics models under different contrast phases was moderate; the optimal AUC values were 0.803 (95% CI: 0.694, 0.913) for the training cohort and 0.775 (95% CI: 0.627, 0.923) for the validation cohort under CEE. The delta-radiomics model under CEE performed better than the optimal 1st-radiomics model under CEE (DeLong test: \( p = 0.054/0.500 \) for the training/validation cohort). Figure 3 shows the LASSO selection process, and Figure 4a presents the results of logistic regression for the delta-radiomics model.
Figure 3. Feature selection for LASSO of the delta-radiomics features. (a) Tuning parameter ($\lambda$) selection by 5-fold cross-validation with minimum criteria. Binomial deviance ($y$-axis) was plotted against $\log(\lambda)$ ($x$-axis). The left dotted vertical line was at the optimal lambda value point by using the minimum criteria, and the right line was at the optimal lambda value point by using one standard error of the minimum criteria (the 1-SE criteria). The optimal value of $\lambda$ was 0.054 (minimum), and the corresponding value of $\log(\lambda) = -2.919$. (b) The least absolute shrinkage and selection operator coefficient profiles of the 80 radiomic features after univariate analysis. For the optimal $\lambda$, nine features with non-zero coefficients were selected.

Figure 4. Odds ratio (OR) values and coefficients of the selected radiomic features in the delta-radiomics model and the longitudinal fusion radiomic model based on CEe. (a) A total of 9 key
features are in the delta-radiomics model, which is the optimal separate radiomic model. (b) The selected 5 features were 2 baseline and 3 delta-radiomics features in the fusion radiomic model of pre-radiomics features and delta-radiomics features. (c) The fusion radiomic model of 1st-radiomics features and delta-radiomics features retains 7 features, 6 from delta-radiomics features and 1 from 1st-radiomics features. (d) A total of 5 features of the fusion radiomic-models of all features based on CEe, and 1 from pre-radiomics features, 1 from 1st-radiomics features, and 3 from delta-radiomics features.

3.4. Determination of the Optimal Contrast Phase

By comparing the model performance, we found that the delta-radiomics model based on the changes in radiomic features achieved superior performance compared to the other models, and CEe was the optimal contrast phase for pCR classification. The ROC curves of all the separate radiomic models are shown in Supplementary Figure S2.

3.5. Longitudinal Fusion Radiomic Model under the Optimal Contrast Phase

Under the optimal contrast phase (CEe), the delta-radiomics features were separately fused with the pre- and 1st-radiomics features to build longitudinal fusion models. Table 3 shows the performances of the longitudinal fusion models. For the fusion of delta- and pre-radiomics features, the selected five features were three delta-radiomics features and two pre-radiomics features, which achieved AUC values of 0.866/0.750 for the training/validation cohort. The corresponding OR values and coefficients of key features for the fusion radiomic models are shown in Figure 4b.

Table 3. Predictive performance of the longitudinal fusion radiomic models and clinical-radiomics models based on the early phase.

| Model Type | AUC     | Sensitivity | Specificity | Accuracy |
|------------|---------|-------------|-------------|----------|
| Longitudinal fusion radiomic models (training/validation) |         |             |             |          |
| Pre + delta | 0.866/0.750 | 0.929/0.833 | 0.623/0.700 | 0.723/0.738 |
| 1st + delta | 0.903/0.839 | 0.821/0.667 | 0.871/0.933 | 0.857/0.857 |
| Pre + 1st + delta | 0.871/0.869 | 0.750/0.667 | 0.871/0.900 | 0.837/0.833 |
| Clinical-radiomic model (training/validation) |         |             |             |          |
| Pre + clinical | 0.762/0.569 | 0.679/0.333 | 0.757/0.900 | 0.735/0.738 |
| 1st + clinical | 0.801/0.767 | 0.786/0.833 | 0.771/0.633 | 0.776/0.691 |
| Delta + clinical | 0.934/0.864 | 0.927/0.750 | 0.829/0.867 | 0.857/0.833 |
| Pre + delta + clinical | 0.870/0.736 | 0.821/0.667 | 0.757/0.800 | 0.776/0.762 |
| 1st + delta + clinical | 0.908/0.828 | 0.821/0.667 | 0.900/0.967 | 0.878/0.881 |
| Pre + 1st + delta + clinical | 0.866/0.864 | 0.714/0.667 | 0.886/0.900 | 0.837/0.833 |

When the delta- and 1st-radiomics features were fused, six of the selected seven features were delta-radiomics features (Figure 4c). The resulting fusion model achieved AUC values of 0.903/0.839 for the training/validation cohort. This fusion model did not show improved performance compared to the delta-radiomics model (AUC = 0.917/0.842 for the training/validation cohort).

A total of five features were conserved from the fusion model of the pre-, 1st-, and delta-radiomics features. Compared with the delta-radiomics model (AUC = 0.917/0.842 for the training/validation cohort), the AUC values (AUC = 0.871/0.869 for the training/validation cohort) showed a slight improvement for the validation cohort. Among the selected features, three were delta-radiomics features, one was a 1st-radiomics feature, and one was a pre-radiomics feature. The corresponding OR values and coefficients are shown in Figure 4d. The longitudinal fusion model showed good agreement between the actual observations and classifications in both the training cohort (Figure 5a) and validation cohort (Figure 5b). Nonsignificant statistics were achieved in the Hosmer–Lemeshow test in the training cohort (p = 0.388) and validation cohort (p = 0.185). DCA showed that the radiomic model would
add more benefit in distinguishing pCR and non-pCR when the threshold probability was at any threshold in the training cohort (Figure 5c) or between 15% to 82% in the validation cohort (Figure 5d).

Figure 5. Calibration curves and decision curve analysis (DCA) for the optimal delta-radiomics model, longitudinal fusion-radiomics model, and clinical-radiomics model. (a) Calibration curves for the training cohort. (b) Calibration curves for the validation cohort. The dotted line represents a perfect classification. (c) DCA results for the training cohort. (d) DCA results for the validation cohort. The y-axis represents the net benefit. The solid gray line represents the scenario that all patients were included in the pCR group. The solid black line represents the scenario that no patients were included in the pCR group. The x-axis represents the threshold probability (i.e., where the expected benefit of the treatment is equal to the expected benefit of avoiding treatment).

3.6. Clinical-Radiomics Models

After adding significant clinical features (HR and HER2) to the radiomic models, the delta-radiomics model still produced the highest AUC (AUC = 0.934/0.864, sensitivity = 0.927/0.750, specificity = 0.829/0.867, accuracy = 0.857/0.833 for the training/validation cohort). Figure 6 shows the ROC curves for the optimal separate radiomic models, longitudinal fusion radiomic models, and clinical-radiomics model. The calibration curves and DCA results of the training set for the clinical-radiomics models are shown in Figure 5. The clinical-radiomics model showed good diagnostic performance based on the actual observations and classifications in the training cohort (Figure 5a) and validation cohort (Figure 5b). Nonsignificant statistics were achieved in the Hosmer-Lemeshow test in the training cohort ($p = 0.910$) and validation cohort ($p = 0.410$). DCA indicated that the clinical-radiomics model was most beneficial in distinguishing pCR and non-pCR when
the threshold probability was between 0 and 0.82 in the training cohort (Figure 5c) or at any given threshold probability in the validation cohort (Figure 5d).

Figure 6. Receiver operating characteristic (ROC) curves of the delta-radiomics model, the longitudinal fusion radiomic model, the clinical-radiomics model in training cohort (a) and validation cohort (b) based on CEe. Numbers in parentheses are areas under the receiver operating characteristic curve (AUC).

3.7. Changes in Radiomic Features in the Delta-Radiomics Model

The nine selected radiomic features in the delta-radiomics model and their values before NAC and after the first cycle of NAC are shown in Table 4. The nine radiomic features included two describing the heterogeneity of the high-gray region, one describing the heterogeneity of the low-gray region, two describing the local homogeneity of the image, one measuring the skewness and asymmetry of GLCM, one measuring the average gray-level intensity within the VOI, one reflecting the similarity between gray-level intensity values, and one gray value–voxel correlation parameter. The feature reflecting the similarity between the gray intensity values (wavelet—LLH_glrml_Gray Level Non-Uniformity Normalized) was upregulated after early treatment, and have higher levels in the pCR group. All other characteristics were downregulated after early treatment, with a greater decrease in the pCR group. Eight of the nine features were wavelet-transformed types. Four features (wavelet—HHH_glszm_Large Area Low Gray Level Emphasis, wavelet—HLH_gldm_Large Dependence High Gray Level Emphasis, and wavelet—LHH_gldm_Large Dependence High Gray Level Emphasis and wavelet—LLH_first order_Mean) from wavelet-transformed type describing the information of gray level. An example of a wavelet-transformed feature wavelet—HLH_gldm_Large Dependence High Gray Level Emphasis (OR = 2.164), which is also retained in the longitudinal fusion radiomic models and is an important feature in the fusion model of pre- and delta-radiomics features (OR = 3.213), the fusion radiomic model of 1st- and delta-radiomics features (OR = 3.213), and the fusion radiomic models of pre-, 1st-, and delta-radiomics features (OR = 3.936). Figure 7 shows the changes in this feature between pre-NAC and 1st-NAC.
Table 4. The nine key radiomic features in the delta-radiomics model and their pre-radiomics and 1st-radiomics features.

| Feature Type         | Median (IQR) Pre | Median (IQR) 1st | Delta | Median (IQR) Non-pCR | Median (IQR) pCR | Trend |
|----------------------|-----------------|-----------------|-------|----------------------|-----------------|-------|
| First order-related  |                 |                 |       |                      |                  |       |
| Correlation (×10^1)  | 7.2 (6.2, 8.0)  | 6.2 (5.2, 7.5)  | 0.9 (0.03, 1.7) | 7.4 (6.5, 8.0)  | 7.0 (6.0, 7.8) | 0.3 (−0.3, 0.8) Down |
| LLH_Mean (×10^1)     | 9.9 (9.9, 10.0) | 9.8 (9.8, 9.9)  | 0.1 (0.03, 0.2) | 9.9 (9.9, 10.0) | 9.9 (9.8, 10.0) | 0.06 (−0.09, 0.08) Down |
| GLCM-related features|                 |                 |       |                      |                  |       |
| HHH_Ldtn (×10^3)     | 3.0 (0.9, 6.2)  | 1.73 (0.4, 3.0) | 1.1 (0.1, 3.4) | 2.3 (1.1, 4.2)  | 2.0 (0.8, 4.2) | 0.2 (−1.2, 1.4) Down |
| LLH_Idn (×10^3)      | 9.2 (9.1, 9.3)  | 9.1 (8.9, 9.2)  | 0.1 (0.04, 0.2) | 9.2 (9.1, 9.3) | 9.2 (9.1, 9.3) | 0.05 (−0.02, 0.13) Down |
| GLD-related features |                 |                 |       |                      |                  |       |
| HLH_LDHGLE (×10^1)   | 8.5 (6.0, 12)   | 4.7 (2.8, 7.6)  | 3.5 (0.9, 6.0) | 9.5 (5.9, 16.0) | 6.6 (4.2, 11.2) | 2.4 (−0.6, 4.9) Down |
| LHH_LDHGLE (×10^1)   | 1.0 (0.6, 1.6)  | 0.6 (0.3, 1.0)  | 0.3 (0.005, −1.1) | 1.2 (0.7, 1.8) | 0.7 (0.6, 2.7) | 0.3 (0.05, −0.7) Down |
| GLSZM-related features|                |                 |       |                      |                  |       |
| HHH_LALGLE (×10^1)   | 0.9 (0.2, 6.3)  | 0.4 (0.05, 6.1) | 0.2 (0.04, 1.1) | 1.6 (0.4, 5.9)  | 0.9 (0.2, 5.0) | 0.1 (−0.9, 1.3) Down |
| GLNL-related features|                 |                 |       |                      |                  |       |
| LLH_GLNUN (×10^2)    | 0.9 (0.7, 1.2)  | 1.0 (0.8, 1.3)  | −0.1 (−0.3, 0.02) | 0.9 (0.7, 1.1) | 0.9 (−0.8, 1.2) | −0.03 (−0.2, 0.1) Up |

HHH, HLH, LHH, and LLH indicate that the feature type is a wavelet transform feature. IQR, interquartile range. LALGLE, large area low gray level emphasis; LDHGLE, large dependence high gray level emphasis; GLNUN, gray level non-uniformity normalized.

Figure 7. Examples feature of wavelet—HHL_gldm_ Large Dependence High Gray Level Emphasis (LDHGLE) in non-pCR and pCR. (A) Images from a non-pCR breast cancer patient (aged 57 years old with invasive ductal carcinoma of the triple negative subtype. The first line is: (a) the image of pre-NAC, (b) ROI, and (c) a LDHGLE map of tumor ROI (mean LDHGLE value = 4268). The second line is: (d) the image of the first cycle of NAC(1st-NAC), (e) ROI, and (f) a LDHGLE map of tumor ROI (mean LDHGLE value = 4240). (B) Images from a pCR breast cancer patient (aged 51 years old with invasive ductal carcinoma of the triple negative subtype. The first line is: (g) the image of pre-NAC, (h) ROI, and (i) a LDHGLE map of tumor ROI (mean LDHGLE value = 4230). The second line is: (j) the image of the first cycle of NAC(1st-NAC), (k) ROI, and (l) a LDHGLE map of tumor ROI (mean LDHGLE value = 4240).
with invasive ductal carcinoma of luminal B subtype). The first line is: (g) the image of pre-NAC, (h) ROI, and (i) a LDHGLE map of tumor ROI (mean LDHGLE value = 16,530). The second line is: (j) the image of 1stNAC, (k) ROI, and (l) a LDHGLE map of tumor ROI (mean LDHGLE value = 10,343). (C) Boxplot represents the feature of wavelet-HHL_ gldm_ LDHGLE distribution among patients of non-pCR and pCR in the training cohort. (D) The heatmap of selected feature in delta-radiomics model based on early phase. Demonstrates overall distribution of key delta-radiomics features among patients with pCR and non-pCR in the training cohort, which shows the obvious difference between the two groups. LDHGLE, large dependence high gray level emphasis.

4. Discussion

The early prediction of treatment response of locally advanced breast cancer to NAC is important for optimizing and adjusting the treatment plan. Our study demonstrated that DCE-MRI-based delta-radiomics after the first cycle of NAC can quantify changes in tumor heterogeneity at the earliest time point. It improved prediction ability using single time-point images (e.g., pre-NAC). Additionally, by comparing the early, peak, and delayed DCE-MRI radiomic models, the optimal contrast phase was preliminarily confirmed to be the early contrast phase, providing a reference for extracting reliable and comparable DCE-MRI data for subsequent radiomics studies.

Many studies [18–20] have focused on pre-NAC radiomics for pCR prediction in breast cancer. In studies on multimodal radiomics, pre-radiomics models based on contrast-enhanced T1-weighted images did not show surprising performance for pCR classification [18–20]. In a large multi-center study [18], Liu et al. found that the AUC achieved by DCE-MRI in the peak phase was less than 0.60. DCE-MRI remains the most essential among a wide range of technologies because its high spatial resolution allows it to precisely reveal tumor size, shape, and internal heterogeneity, thus facilitating the tumor segmentation. Breast DCE-MRI for evaluating the treatment response is recommended every two NAC cycles by expert consensus [36]. The changes in tumor size [8,9,37] and functional parameters [7,11] based on DCE-MRI after two NAC cycles and even after one cycle strongly predicted the final therapeutic response. Recent studies extended the longitudinal changes to texture [14–16] and radiomic features [25,26]. Delta-radiomics features after early treatment reflect therapy-induced changes in tumor morphology and heterogeneity, which may improve the performance of single pre-NAC images. Eun et al. [14] found that DCE-MRI texture-based models from a single time-point (after three or four cycles of NAC) had the highest diagnostic performance (AUC, 0.82; 95% CI: 0.74, 0.8). However, the middle stage of the NAC treatment is too late to make changes to the regimen in patients for whom NAC is ineffective. In another small-sample study [16], Nadrljanski et al. found that DCE-MRI performed after two NAC cycles could reveal the differences in texture features between patients that respond and do not respond to NAC. Advancing scanning time point after the first cycle of NAC, we extracted comprehensive radiomic features from DCE-MRI before and after the first cycle, analyzed their differences, and built an optimal model for the earlier and more accurate prediction of patient outcomes. Recent studies [38,39], which used deep learning and transfer learning for feature extraction and selection without human intervention, have been already successfully applied on pre-treatment and early-treatment DCE-MRI and achieved a good performance. Some difficulties have been recently overcome thanks to deep learning, such as time-consuming manual labeling, inconsistent DCE-MRI protocols, etc. Furthermore, fully automatic segmentation is not restricted to intratumoral features, breast tissue [40] and peritumoral [41] can also give an early prediction. This is the direction of our further efforts.

Although the DCE-MRI scanning sequence varied among studies, the early phase [14,19,20,37] and peak phase [18,19,25] are the most commonly used phases for extracting DCE-MRI radiomic features. Based on DCE-MRI under the peak contrast phase, Fan et al. [25] explored the delta-radiomics features after the second NAC cycle. The diagnostic power obtained using the first cycle data in our study (AUC = 0.764 for
delta-radiomics) was similar to that achieved by the second cycle data of Fan et al. [25] (AUC = 0.726 for delta-radiomics). We extracted features under multiple contrast phases and found that the early phase performed better than the peak or delay phases. The reason may be that our DCE-MRI used the DISCO protocol. DISCO provides higher temporal and comparable spatial resolution compared with clinical standard protocol [26,42]. This advantage is beneficial for detection and classification of breast lesions with high accuracy [43,44]. High temporal resolution makes the phase capture more accurate, especially for malignant tumors with rapid early enhancement. High spatial resolution guarantees the accuracy of radiomic features because high spatial resolution leads to better classification compared with low spatial resolution [34]. Despite the noted strengths, the clinical application of DISCO is still in its infancy and remains exploratory. The first issue to address is the storage and transmission difficulties caused by big data volumes. The absence of clear guidelines for quantitative measurement is another current issue. Tumor segmentation in the different contrast phases influences DCE-MRI parameter measurement, and the early phase is optimal for the extraction of reliable DCE-MRI kinetic parameters [45]. The early phase of DCE-MRI is recommended for response monitoring following chemotherapy and pCR prediction [46]. Our findings further confirm that the early phase should be used in radiomics studies. The most informative feature values for tumor characterization should be available at two minutes or less after the injection of contrast agent [47]. A possible explanation for this might be that the cumulative difference of the contrast agents for each voxel in early phase highlighted tumor heterogeneity, while these differences tend to balance in the peak/delay phases. Thus, peak- or delayed-phase imaging may not provide the most valuable feature information for predicting pCR.

Features from delta-radiomics account for the largest proportion of longitudinal fusion radiomic models. This is consistent with our hypothesis: the delta-radiomics features reflected the therapy-induced changes in tumor heterogeneity, allowing the prediction of pCR. After adding clinical factors (HR and HER2 status) to the delta-radiomics model, the clinical-radiomics model achieved an AUC of 0.934/0.864 in the training/validation cohort. Thus, combining clinicopathological information with delta-radiomics is effective in predicting the performance of pCR in breast cancer patients. Focusing on the meanings of radiomic features, Zhou et al. [32] found that the features of wavelet-transformed feature showed promise for predicting pCR in response to NAC for patients with breast cancer, which supports our results. Among the key wavelet-transformed features based on the delta-radiomics model in our study, the three most important features were wavelet—LLH_glcm_Idn, wavelet—LLH_firstorder_Mean, and wavelet—HLH_gldm_Large Dependence High Gray Level Emphasis. All of these features were downregulated after early treatment and were significantly higher in pCR patients than in non-pCR patients. This can be explained by the different changes in tumor heterogeneity observed in the two response groups. Among the three most important wavelet-transformed features, two reflect the gray level of the entire tumor. The feature wavelet—HLH_gldm_Large Dependence High Gray Level Emphasis was important in all longitudinal fusion radiomic models and showed good robustness for predicting pCR. This further indicates that heterogeneous changes of high proliferative activity area with high-gray in DCE-MRI better cast light upon pCR. The large dependence high gray-level emphasis of Jacobian maps (a registered map that reflects the level of voxelwise volumetric shrink or expansion) in Fan et al. [25] also found to be higher in non-responders than responders after the second cycle of NAC. In the current study, considering that Jacobian map did not show better performance than the delta-radiomics models, we analyzed feature-level delta-radiomics features without voxelwise-level changes. Jahani et al. [48] reported the changes in voxelwise first-order features resulted in better pCR prediction compared with feature-level Changes. It is worth applying radiomics to maps of voxelwise features changes in future research. We also found that the feature original—glcm_Correlation, which reflects the correlation of local gray levels in the image, was also important in the delta-radiomics model and the fusion models. The value of this feature was downregulated after early treatment and was significantly
higher in pCR patients than in non-pCR patients. Thus, gray scale related features also play an important role in predicting pCR.

Despite the considerable diagnostic power of delta-radiomics using longitudinal images, several limitations of this pilot study should be acknowledged. First, the sample size of the prospective cohort was relatively small. Further studies with large numbers of patients from multiple centers should be conducted to confirm our findings. Second, the different cancer subtypes included in our study are treated by different NAC regimens, although we affirmed that all NAC regimens were standard. Third, we only detected feature-level changes; we did not evaluate voxel-level changes. Fourth, DISCO protocol with high spatiotemporal resolution is conducive to quantitative and semi-quantitative measurements, while we did not compare or combine radiomics with quantitative parameters. Finally, there is no clear biological explanation for radiomic features and their changes, and interpretability remains the biggest limitation of current radiomics studies.

5. Conclusions

Delta-radiomics characterizing the change in feature values by applying radiomics to multiple time points, is a promising strategy for predicting pCR after NAC. Using DCE-MRI evaluations before and after one NAC cycle, delta-radiomics under the early contrast phase combined with clinicopathological information has excellent predictive power for pCR prediction.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/cancers14143515/s1. Data S1: Definition of radiomic features; Data S2: Key features from the separate radiomic models; Figure S1: The process of differential subsampling with Cartesian ordering dynamic contrast-enhanced (DISCO) DCE-MRI in this study; Figure S2: ROC curves of the separate radiomic models.

Author Contributions: Conceptualization, S.D., S.G. and L.Z.; methodology, L.G., S.D., S.G., L.Z., YT. and FJ.; validation, L.G., S.D., S.G. and L.Z.; formal analysis, L.Z.; investigation, L.G., R.Z., G.H.; data curation, L.G., R.Z. and G.H.; writing—original draft preparation, L.G.; writing—review and editing, S.D. and L.Z.; supervision, L.Z., Y.T., FJ. All authors have read and agreed to the published version of the manuscript.

Funding: This research was supported by the National Natural Science Foundation of China (81971695) and the Set Sail Project of the First Affiliated Hospital of China Medical University (36028).

Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Review Board (or Ethics Committee) of the First Affiliated Hospital of China Medical University (Ethic code: 2019-33-2 with date of approval 6 March 2019).

Informed Consent Statement: Written informed consent has been obtained from the patient(s) to publish this paper.

Data Availability Statement: The data presented in this study are available on reasonable request from the corresponding author L.Z., zhanglnda@163.com. Due to privacy restrictions the data are not publicly available.

Acknowledgments: We sincerely appreciate Min Zhao and Yan Guo from the Department of Core Imaging, Life Science, GE healthcare, Shanghai, China, for her assistance in the data processing and statistical analysis.

Conflicts of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References

1. Derks, M.G.M.; van de Velde, C.J.H. Neoadjuvant chemotherapy in breast cancer: More than just downsizing. *Lancet Oncol.* 2017, 19, 2–3. [CrossRef]

2. Spring, L.; Greenup, R.; Reynolds, K.; Smith, B.L.; Moy, B.; Bardia, A. Abstract 1439: Pathological complete response after neoadjuvant chemotherapy predicts improved survival in all major subtypes of breast cancer: Systematic review and meta-analyses of over 18,000 patients. *Cancer Res.* 2016, 76, 1439. [CrossRef]

3. Haque, W.; Verma, V.; Hatch, S.; Klimberg, V.S.; Butler, E.B.; Teh, B.S. Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy. *Breast Cancer Res. Treat.* 2018, 170, 559–567. [CrossRef] [PubMed]

4. Davey, M.G.; Kerin, E.; O’Flaherty, C.; Maher, E.; Richard, V.; McNenney, P.F.; McLaughlin, R.P.; Sweeney, K.J.; Barry, M.K.; Malone, C.M.; et al. Clinicopathological response to neoadjuvant therapies and pathological complete response as a biomarker of survival in human epidermal growth factor receptor-2 enriched breast cancer—A retrospective cohort study. *Breast* 2021, 59, 67–75. [CrossRef] [PubMed]

5. Mann, R.M.; Kuhl, C.K.; Kinkel, K.; Boetes, C. Breast MRI: Guidelines from the European Society of Breast Imaging. *Clin. Imaging* 2008, 32, 1307–1318. [CrossRef] [PubMed]

6. Fowler, A.M.; Mankoff, D.A.; Joe, B.N. Imaging Neoadjuvant Therapy Response in Breast Cancer. *RadioGraphics* 2017, 38, 351–368. [CrossRef] [PubMed]

7. Padhani, A.R.; Hayes, C.; Assersohn, L.; Powles, T.; Makris, A.; Suckling, J.; Leach, M.; Husband, J.E. Prediction of Clinicopathologic Response of Breast Cancer to Primary Chemotherapy at Contrast-enhanced MR Imaging: Initial Clinical Results. *Radiology* 2006, 239, 361–374. [CrossRef]

8. Minarikova, L.; Bogner, W.; Pinker, K.; Valkovic, L.; Zaric, O.; Bago-Horvath, Z.; Bartsch, R.; Helbich, T.H.; Trattnig, S.; Gruber, S. Investigating the prediction value of multiparametric magnetic resonance imaging at 3 T in response to neoadjuvant chemotherapy in breast cancer. *Eur. Radiol.* 2016, 27, 1901–1911. [CrossRef]

9. Hylton, N.M.; Blume, J.D.; Bernard, W.; Pisano, E.D.; Morris, E.A.; Weatherall, P.T.; Lehman, C.D.; Newsom, A.; Polin, S.; et al. ACRIN 6657 Trial Team and I-SPY 1 TRIAL Investigators. Locally advanced breast cancer MRI imaging for prediction of response to neoadjuvant chemotherapy-results from ACRIN 6657 or 1-SPY TRIAL. *Radiology* 2012, 263, 663–672. [CrossRef]

10. Tunodora, A.; Oh, J.Y.; Chui, S.Y.C.; Roy, N.; Troxell, M.L.; Naik, A.; Kemmer, K.A.; Chen, Y.; Holtorf, M.L.; Afzal, A.; et al. Early Prediction and Evaluation of Breast Cancer Response to Neoadjuvant Chemotherapy Using Quantitative DCE-MRI. *Transl. Oncol.* 2016, 9, 8–17. [CrossRef]

11. Li, X.; Arlinghausen, L.R.; Ayers, G.D.; Chakravarty, A.B.; Abramson, R.G.; Abramson, V.G.; Atuegwu, N.; Farley, J.; Mayer, I.A.; Kelley, M.C.; et al. DCE-MRI analysis methods for predicting the response of breast cancer to neoadjuvant chemotherapy: Pilot study findings. *Magn. Reson. Med.* 2013, 71, 1592–1602. [CrossRef] [PubMed]

12. Dogan, B.E.; Yuan, Q.; Bassett, H.; Guvenc, I.; Jackson, E.F.; Cristofanilli, M.; Whitman, G.J. Comparing the Performances of Magnetic Resonance Imaging Size vs Pharmacokinetic Parameters to Predict Response to Neoadjuvant Chemotherapy and Survival in Patients With Breast Cancer. *Curr. Probl. Diagn. Radiol.* 2019, 48, 235–240. [CrossRef] [PubMed]

13. Pereira, N.P.; Curi, C.; Osorio, C.A.B.T.; Marques, E.F.; Makdisi, F.B.; Pinker, K.; Bitencourt, A.G.V. Diffusion-Weighted Magnetic Resonance Imaging of Patients with Breast Cancer Following Neoadjuvant Chemotherapy Provides Early Prediction of Pathological Response—A Prospective Study. *Sci. Rep.* 2019, 9, 16372. [CrossRef]

14. Eun, N.L.; Kang, D.; Son, E.J.; Park, J.S.; Youk, J.H.; Kim, J.-A.; Gweon, H.M. Texture Analysis with 3.0-T MRI for Association of Response to Neoadjuvant Chemotherapy in Breast Cancer. *Radiology* 2020, 294, 31–41. [CrossRef] [PubMed]

15. Henderson, S.; Purdie, C.; Michie, C.; Evans, A.; Lerski, R.; Johnston, M.; Vinnicombe, S.; Thompson, A.M. Interim heterogeneity changes measured using entropy texture features on T2-weighted MRI at 3.0 T are associated with pathological response to neoadjuvant chemotherapy in primary breast cancer. *Eur. Radiol.* 2017, 27, 4602–4611. [CrossRef] [PubMed]

16. Narodzinski, M.M.; Milosevic, Z.C. Tumor texture parameters of invasive ductal breast carcinoma in neoadjuvant chemotherapy: Early identification of non-responders on breast MRI. *Clin. Imaging* 2020, 65, 119–123. [CrossRef] [PubMed]

17. Granzier, R.; van Nijnatten, T.; Woodruff, H.; Smidt, M.; Lobbes, M. Exploring breast cancer response prediction to neoadjuvant systemic therapy using MRI-based radiomics: A systematic review. *Eur. J. Radiol.* 2019, 121, 108736. [CrossRef]

18. Liu, Z.; Li, Z.; Qu, J.; Zhang, R.; Zhou, X.; Li, L.; Sun, K.; Tang, Z.; Jiang, H.; Li, H.; et al. Radiomics of Multiparametric MRI for Pretreatment Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer: A Multicenter Study. *Clin. Cancer Res.* 2019, 25, 3538–3547. [CrossRef]

19. Braman, N.M.; Etesami, M.; Prasad, P.; Dubchuk, C.; Gilmore, H.; Tiwari, P.; Plecha, D.; Madabhushi, A. Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI. *Breast Cancer Res.* 2017, 19, 57. [CrossRef]

20. Cain, E.H.; Saha, A.; Harowicz, M.R.; Marks, J.R.; Marcom, P.K.; Mazurowski, M.A. Multivariate machine learning models for prediction of pathologic response to neoadjuvant therapy in breast cancer using MRI features: A study using an independent validation set. *Breast Cancer Res. Treat.* 2018, 173, 455–463. [CrossRef]

21. Shur, J.D.; Doran, S.J.; Kumar, S.; ap Dafydd, D.; Downey, K.; O’Connor, J.P.B.; Papankolakau, N.; Messiou, C.; Koh, D.-M.; Orton, M.R. Radiomics in Oncology: A Practical Guide. *RadioGraphics* 2021, 41, 1717–1732. [CrossRef] [PubMed]
22. Teruel, J.R.; Heldahl, M.G.; Goa, P.E.; Pickles, M.; Lundgren, S.; Batthen, T.F.; Gibbs, P. Dynamic contrast-enhanced MRI texture analysis for pretreatment prediction of clinical and pathological response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. NMR Biomed. 2014, 27, 887–896. [CrossRef] [PubMed]

23. Fan, M.; Wu, G.; Cheng, H.; Zhang, J.; Shao, G.; Li, L. Radiomic analysis of DCE-MRI for prediction of response to neoadjuvant chemotherapy in breast cancer patients. Eur. J. Radiol. 2017, 94, 140–147. [CrossRef]

24. Yu, Y.; He, Z.; Ouyang, J.; Tan, Y.; Chen, Y.; Gu, Y.; Mao, L.; Ren, W.; Wang, J.; Lin, L.; et al. Magnetic resonance imaging radiomics predicts preoperative axillary lymph node metastasis to support surgical decisions and is associated with tumor microenvironment in invasive breast cancer. A machine learning, multicenter study. eBioMedicine 2021, 69, 103460. [CrossRef] [PubMed]

25. Fan, M.; Chen, H.; You, C.; Liu, L.; Gu, Y.; Peng, W.; Gao, X.; Li, L. Radiomics of Tumor Heterogeneity in Longitudinal Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Predicting Response to Neoadjuvant Chemotherapy in Breast Cancer. Front. Mol. Biosci. 2021, 8, 62219. [CrossRef]

26. Morrison, C.K.; Bancroft, L.H.; DeMartini, W.B.; Holmes, J.H.; Wang, K.; Bosca, R.J.; Korosec, F.R.; Striegel, R.M. Novel High Spatiotemporal Resolution Versus Standard-of-Care Dynamic Contrast-Enhanced Breast MRI. Investig. Radiol. 2017, 52, 198–205. [CrossRef]

27. Hammond, M.E.H.; Hayes, D.F.; Dowsett, M.; Allred, D.C.; Hagerty, K.L.; Badve, S.; Fitzgibbons, P.L.; Francis, G.; Goldstein, N.S.; Hayes, M.; et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. J. Clin. Oncol. 2010, 28, 2784–2795. [CrossRef]

28. Wolff, A.C.; Hammond, M.E.H.; Allison, K.H.; Harvey, B.E.; Mangu, P.B.; Bartlett, J.M.S.; Bilous, M.; Ellis, I.O.; Fitzgibbons, P.; Hanna, W.; et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J. Clin. Oncol. 2018, 36, 2105–2122. [CrossRef]

29. Bustreo, S.; Osella-Abate, S.; Cassoni, P.; Donadio, M.; Airoldi, M.; Pedani, F.; Papotti, M.; Sapino, A.; Castellano, I. Optimal Ki67 cut-off for luminal breast cancer prognostic imaging: A large case series study with a long-term follow-up. Breast Cancer Res. Treat. 2016, 157, 363–371. [CrossRef]

30. Curigliano, G.; Burstein, H.J.; Winer, E.P.; Grant, M.; Dubsky, P.; Loibl, S.; Colleoni, M.; Regan, M.M.; Piccart-Gebhart, M.; Senn, H.J.; et al. De-escalating and escalating treatments for early-stage breast cancer: The St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2017, 28, 1700–1712. [CrossRef]

31. Gradishar, W.J.; Anderson, B.O.; Balassanian, R.; Blair, S.L.; Burstein, H.J.; Curr, A.; Elias, A.D.; Farrar, W.B.; Forero, A.; Giordano, S.H.; et al. Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Cancer Netw. 2018, 16, 310–320. [CrossRef]

32. Zhou, J.; Lu, J.; Gao, C.; Zeng, J.; Zhou, C.; Lai, X.; Cai, W.; Xu, M. Predicting the response to neoadjuvant chemotherapy for breast cancer: Wavelet transforming radiomics in MRI. BMC Cancer 2020, 20, 100. [PubMed] [CrossRef]

33. Yushkevich, P.A.; Piven, J.; Hazlett, H.C.; Smith, R.G.; Ho, S.; Gee, J.C.; Gerig, G. User-guided 3D active contour segmentation of medical images. IEEE Trans. Med. Imag. 2006, 25, 1116–1128. [CrossRef]

34. Zheng, X.; Cui, T.; Wang, L.; Pan, T.; Liu, X.; Zhang, A.; Hao, Q.; Huang, L.; et al. Spatiotemporal Resolution Versus Standard-of-Care Dynamic Contrast-Enhanced Breast MRI. Radiomics of MRI for the Prediction of the Pathological Response to Neoadjuvant Chemotherapy in Breast Cancer Patients: A Single Referral Centre Analysis. Cancers 2021, 13, 4271. [CrossRef]

35. Massafr, R.; Comes, M.C.; Bove, S.; Didonna, V.; Gatta, G.; Giotta, F.; Fanizzi, A.; La Forgia, D.; Latorre, A.; Pastena, M.I.; et al. Robustness Evaluation of a Deep Learning Model on Sagittal and Axial Breast DCE-MRIs to Predict Pathological Complete Response to Neoadjuvant Chemotherapy. J. Pers. Med. 2020, 12, 280. [CrossRef]

36. Comes, M.C.; Fanizzi, A.; Bove, S.; Didonna, V.; Diotaiuti, S.; La Forgia, D.; Latorre, A.; Martinelli, E.; Mencatini, A.; Nardone, A.; et al. Early prediction of neoadjuvant chemotherapy response by exploiting a transfer learning approach on breast DCE-MRIs. Sci. Rep. 2021, 11, 14123. [CrossRef]

37. La Forgia, D.; Vestito, A.; Lascirrea, M.; Comes, M.; Diotaiuti, S.; Giotta, F.; Latorre, A.; Lorusso, V.; Massafr, R.; Palmioti, G.; et al. Radiomic response in breast DCE-MRI: A multi-center study in Breast Cancer: A Qualitative Analysis of Background Parenchymal Enhancement in DCE-MRI. J. Pers. Med. 2021, 11, 256. [CrossRef]

38. Qi, T.H.; Hian, O.H.; Kumaran, A.M.; Tan, T.J.; Cong, T.R.Y.; Su-Xin, G.L.; Lim, E.H.; Ng, R.; Yeo, M.C.R.; Tching, F.L.L.W.; et al. Multi-center evaluation of artificial intelligent imaging and clinical models for predicting neoadjuvant chemotheraphy response in breast cancer. Breast Cancer Res. Treat. 2022, 193, 121–138. [CrossRef]
42. Saranathan, M.; Rettmann, D.W.; Hargreaves, B.A.; Lipson, J.A.; Daniel, B.L. Variable spatiotemporal resolution three-dimensional dixon sequence for rapid dynamic contrast-enhanced breast MRI. *J. Magn. Reson. Imaging* **2013**, *40*, 1392–1399. [CrossRef]

43. Milon, A.; Perre, S.V.; Poujol, J.; Trop, I.; Kermarrec, E.; Bekhouche, A.; Thomassin-Naggara, I. Abbreviated breast MRI combining FAST protocol and high temporal resolution (HTR) dynamic contrast enhanced (DCE) sequence. *Eur. J. Radiol.* **2019**, *117*, 199–208. [CrossRef]

44. Perre, S.V.; Duron, L.; Milon, A.; Bekhouche, A.; Balvay, D.; Cornelis, F.H.; Fournier, L.; Thomassin-Naggara, I. Radiomic analysis of HTR-DCE MR sequences improves diagnostic performance compared to BI-RADS analysis of breast MR lesions. *Eur. Radiol.* **2021**, *31*, 4848–4859. [CrossRef]

45. Romeo, V.; Cavaliere, C.; Imbriaco, M.; Verde, F.; Petretta, M.; Franzese, M.; Stanzione, A.; Cuocolo, R.; Aiello, M.; Basso, L.; et al. Tumor segmentation analysis at different post-contrast time points: A possible source of variability of quantitative DCE-MRI parameters in locally advanced breast cancer. *Eur. J. Radiol.* **2020**, *126*, 108907. [CrossRef]

46. Mann, R.M.; Cho, N.; Moy, L. Breast MRI: State of the Art. *Radiology* **2019**, *292*, 520–536. [CrossRef]

47. Macura, K.J.; Ouwerkerk, R.; Jacobs, M.A.; Bluemke, D. Patterns of Enhancement on Breast MR Images: Interpretation and Imaging Pitfalls. *RadioGraphics* **2006**, *26*, 1719–1734. [CrossRef]

48. Jahani, N.; Cohen, E.; Hsieh, M.-K.; Weinstein, S.P.; Pantalone, L.; Hylton, N.; Newitt, D.; Davatzikos, C.; Kontos, D. Prediction of Treatment Response to Neoadjuvant Chemotherapy for Breast Cancer via Early Changes in Tumor Heterogeneity Captured by DCE-MRI Registration. *Sci. Rep.* **2019**, *9*, 12114. [CrossRef]